Want to see FR:ALCGM full AI Analyst Report?
Top Page
Cegedim
(ALCGM)
Select Model
Select Model
Rating:60Neutral
Price Target:
€14.50
▲(36.79% Upside)
Action:Reiterated
Date:10/25/25
Cegedim's overall stock score is primarily influenced by its solid revenue growth and strong technical momentum. However, challenges with profitability, financial stability, and valuation concerns due to a negative P/E ratio and lack of dividend yield weigh down the score. The absence of earnings call data and corporate events means these factors did not influence the score.
Positive Factors
Business model diversification
Multiple, complementary revenue streams (subscriptions, transaction fees, consulting and data services) create durable cash inflows and reduce reliance on any single customer or product. This mix supports predictable recurring revenue and resilience through sector cycles in healthcare IT.
Negative Factors
Negative profitability
Recurring negative net income and shrinking EBIT margins threaten long-term sustainability; without margin recovery, the firm may struggle to self-fund R&D and growth initiatives, risking dilution or debt-funded expansion to maintain competitiveness.
Read all positive and negative factors
Positive Factors
Negative Factors
Business model diversification
Multiple, complementary revenue streams (subscriptions, transaction fees, consulting and data services) create durable cash inflows and reduce reliance on any single customer or product. This mix supports predictable recurring revenue and resilience through sector cycles in healthcare IT.
Read all positive factors
Cegedim (ALCGM) vs. iShares MSCI France ETF (EWQ)
Market Cap
€141.53M
Dividend Yield2.17%
Average Volume (3M)6.14K
Price to Earnings (P/E)―
Beta (1Y)0.66
Revenue Growth-0.81%
EPS GrowthN/A
CountryFR
Employees6,344
SectorGeneral
Sector StrengthN/A
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-1.07
Shares Outstanding14,097,155
10 Day Avg. Volume4,461
30 Day Avg. Volume6,138
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)0.66
Price to Sales (P/S)0.27
P/FCF Ratio14.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.76
Revenue Forecast (FY)€660.43M
Cegedim Business Overview & Revenue Model
Company Description
Cegedim SA operates as a technology and services firm dedicated to digital data flow management within the healthcare ecosystem and business-to-business (B2B) sectors. Its operations extend across France, other European countries, and internationa...
How the Company Makes Money
Cegedim generates revenue through multiple streams, primarily by providing software solutions and data services to healthcare organizations and pharmaceutical companies. Key revenue models include subscription fees for software licenses, transacti...
Cegedim Financial Statement Overview
Summary
Income Statement
60
Neutral
Balance Sheet
55
Neutral
Cash Flow
65
Positive
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 654.50M | 616.00M | 555.21M | 524.71M | 496.94M |
| Gross Profit | 624.93M | 255.63M | 528.65M | 498.01M | 471.45M |
| EBITDA | 101.56M | 95.25M | 94.96M | 103.64M | 60.71M |
| Net Income | -14.71M | -7.41M | 13.62M | 26.22M | 10.84M |
Balance Sheet | |||||
| Total Assets | 986.89M | 924.07M | 889.91M | 797.59M | 905.36M |
| Cash, Cash Equivalents and Short-Term Investments | 49.58M | 46.61M | 55.55M | 24.16M | 24.73M |
| Total Debt | 325.85M | 285.10M | 284.59M | 275.50M | 266.46M |
| Total Liabilities | 704.39M | 629.51M | 585.78M | 565.20M | 697.45M |
| Stockholders Equity | 264.35M | 276.18M | 285.16M | 232.06M | 207.66M |
Cash Flow | |||||
| Free Cash Flow | 11.93M | 22.43M | 10.34M | 45.23M | 35.85M |
| Operating Cash Flow | 101.85M | 97.92M | 86.48M | 95.98M | 110.38M |
| Investing Cash Flow | -111.32M | -75.30M | -20.17M | -70.11M | -69.26M |
| Financing Cash Flow | 13.12M | -31.07M | -33.89M | -26.74M | -45.20M |
Cegedim Technical Analysis
Negative
10.60
Price Trends
10.35
Negative
10.82
Negative
11.63
Negative
Market Momentum
-0.03
Negative
46.99
Neutral
26.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALCGM, the sentiment is Negative. The current price of 10.6 is above the 20-day moving average (MA) of 10.36, above the 50-day MA of 10.35, and below the 200-day MA of 11.63, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 46.99 is Neutral, neither overbought nor oversold. The STOCH value of 26.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALCGM.
Cegedim Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | €666.88M | 17.63 | 13.47% | 2.66% | 11.35% | 2.20% | |
76 Outperform | €54.13M | 17.74 | 13.43% | 0.84% | 8.98% | -11.40% | |
60 Neutral | €141.53M | -9.64 | -5.44% | 2.17% | -0.81% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | €166.37M | 5.65 | 33.68% | 0.58% | -11.89% | 1623.56% | |
43 Neutral | €494.14M | -0.41 | 117.34% | 1.65% | -14.39% | -173.10% | |
41 Neutral | €13.88M | -1.22 | 283.66% | ― | 31.94% | -90.36% |
* General Sector Average
FR:ALCGM
Cegedim
10.32
0.12
1.18%
FR:ATO
Atos SE
24.82
-21.18
-46.04%
FR:AUB
Aubay Société Anonyme
52.70
10.19
23.97%
FR:BLC
Bastide le Confort Medical
22.60
-2.40
-9.60%
FR:COH
Coheris
9.58
0.64
7.13%
FR:ALINS
Intrasense SA
0.25
-0.05
-16.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.